345 related articles for article (PubMed ID: 25475205)
21. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
[TBL] [Abstract][Full Text] [Related]
22. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of novel triazolyl quinoline derivatives as potential antileishmanial agents.
Upadhyay A; Kushwaha P; Gupta S; Dodda RP; Ramalingam K; Kant R; Goyal N; Sashidhara KV
Eur J Med Chem; 2018 Jun; 154():172-181. PubMed ID: 29793211
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy of leishmaniasis. Part XII: design, synthesis and bioevaluation of novel triazole integrated phenyl heteroterpenoids as antileishmanial agents.
Suryawanshi SN; Tiwari A; Kumar S; Shivahare R; Mittal M; Kant P; Gupta S
Bioorg Med Chem Lett; 2013 May; 23(10):2925-8. PubMed ID: 23582274
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and Antileishmanial Activity of 1,2,4,5-Tetraoxanes against
Cabral LIL; Pomel S; Cojean S; Amado PSM; Loiseau PM; Cristiano MLS
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979089
[TBL] [Abstract][Full Text] [Related]
26. Aminothiazoles: Hit to lead development to identify antileishmanial agents.
Bhuniya D; Mukkavilli R; Shivahare R; Launay D; Dere RT; Deshpande A; Verma A; Vishwakarma P; Moger M; Pradhan A; Pati H; Gopinath VS; Gupta S; Puri SK; Martin D
Eur J Med Chem; 2015 Sep; 102():582-93. PubMed ID: 26318065
[TBL] [Abstract][Full Text] [Related]
27. A new Heck reaction modification using ketone Mannich bases as enone precursors: parallel synthesis of anti-leishmanial chalcones.
Reichwald C; Shimony O; Sacerdoti-Sierra N; Jaffe CL; Kunick C
Bioorg Med Chem Lett; 2008 Mar; 18(6):1985-9. PubMed ID: 18276134
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy of leishmaniasis part X: synthesis and bioevaluation of novel terpenyl heterocycles.
Tiwari A; Kumar S; Suryawanshi SN; Mittal M; Vishwakarma P; Gupta S
Bioorg Med Chem Lett; 2013 Jan; 23(1):248-51. PubMed ID: 23177254
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of oxysterols and nitrogenous sterols with antileishmanial and trypanocidal activities.
Bazin MA; Loiseau PM; Bories C; Letourneux Y; Rault S; El Kihel L
Eur J Med Chem; 2006 Oct; 41(10):1109-16. PubMed ID: 16949702
[TBL] [Abstract][Full Text] [Related]
30. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
Kumar D; Kulshrestha A; Singh R; Salotra P
Antimicrob Agents Chemother; 2009 Feb; 53(2):835-8. PubMed ID: 19015344
[TBL] [Abstract][Full Text] [Related]
31. Leishmania donovani: effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate.
Valiathan R; Dubey ML; Mahajan RC; Malla N
Exp Parasitol; 2006 Oct; 114(2):103-8. PubMed ID: 16616137
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model.
Utaile M; Kassahun A; Abebe T; Hailu A
Exp Parasitol; 2013 May; 134(1):68-75. PubMed ID: 23434530
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of new [1,2,4]triazino[5,6-b]indol-3-ylthio-1,3,5-triazines and [1,2,4]triazino[5,6-b]indol-3-ylthio-pyrimidines against Leishmania donovani.
Gupta L; Sunduru N; Verma A; Srivastava S; Gupta S; Goyal N; Chauhan PM
Eur J Med Chem; 2010 Jun; 45(6):2359-65. PubMed ID: 20371140
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
35. Antileishmanial activity of drug infused mini-agar plates on Leishmania donovani promastigotes.
Muniaraj M; Sinha PK; Das P
Trop Biomed; 2010 Dec; 27(3):657-61. PubMed ID: 21399608
[TBL] [Abstract][Full Text] [Related]
36. The antileishmanial properties of surface-modified, primaquine-loaded nanocapsules tested against intramacrophagic Leishmania donovani amastigotes in vitro.
Heurtault B; Legrand P; Mosqueira V; Devissaguet JP; Barratt G; Bories C
Ann Trop Med Parasitol; 2001 Jul; 95(5):529-33. PubMed ID: 11487374
[No Abstract] [Full Text] [Related]
37. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
Sinha R; Roychoudhury J; Palit P; Ali N
Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of 2-(pyrimidin-2-yl)-1-phenyl-2,3,4,9-tetrahydro-1H-beta-carbolines as antileishmanial agents.
Kumar R; Khan S; Verma A; Srivastava S; Viswakarma P; Gupta S; Meena S; Singh N; Sarkar J; Chauhan PM
Eur J Med Chem; 2010 Aug; 45(8):3274-80. PubMed ID: 20457476
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series.
Van den Kerkhof M; Mabille D; Chatelain E; Mowbray CE; Braillard S; Hendrickx S; Maes L; Caljon G
Int J Parasitol Drugs Drug Resist; 2018 Apr; 8(1):81-86. PubMed ID: 29425734
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of Unsymmetrical Sulfides and Their Oxidation to Sulfones to Discover Potent Antileishmanial Agents.
Dar AA; Enjamuri N; Shadab M; Ali N; Khan AT
ACS Comb Sci; 2015 Nov; 17(11):671-81. PubMed ID: 26441303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
